What's new? Log in Free sign up

Table search / FibroBiologics, Inc. Common Stock / "Tax"

12 results

Newest first Best match first

DEF 14A

FBLG FibroBiologics, Inc. Common Stock

8 Jul 24

Definitive proxy

11:23am

WithumSmith+Brown, PC

	Year Ended December 31,
	2023		2022
Audit Fees(1)	$	268,482	$	117,450
Audit-Related Fees		—		—
Tax Fees		—		—
Total Fees	$	268,482	$	117,450

S-1/A

FBLG FibroBiologics, Inc. Common Stock

IPO registration (amended)


	Years Ended December 31,
	2023			2022
Federal statutory rate		(21.0	)%		(21.0	)%
Permanent items		9.2			0.8
True-up prior-year net operating loss deferred tax asset		—			(6.1)
Non-deductible stock compensation		1.6			0.0
Other changes		—			1.9
Change in valuation allowance		10.2			24.4	%
Total		0.0	%		0.0	%

26 Mar 24

5:28pm

S-1/A

FBLG FibroBiologics, Inc. Common Stock

IPO registration (amended)


(in thousands of dollars)	December 31, 2023		December 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$	2,005	$	896
Capitalized research and development		675		299
Lease liability		367		435
Accrued liabilities		156		81
Stock compensation		123		17
Derivative liability		—		31
Deferred tax assets		3,326		1,759
Deferred tax liabilities:
Lease right-of-use asset		(380)		(462)
Fixed assets		(11)		—
Unamortized debt discount		—		(31)
Deferred tax liabilities		(391)		(493)
Less: Valuation allowance		(2,935)		(1,266)
Net deferred tax assets	$	—	$	—

26 Mar 24

5:28pm

S-1/A

FBLG FibroBiologics, Inc. Common Stock

IPO registration (amended)


	Years Ended December 31,
	2023			2022
Federal statutory rate		(21.0	)%		(21.0	)%
Permanent items		9.2			0.8
True-up prior-year net operating loss deferred tax asset		—			(6.1)
Non-deductible stock compensation		1.6			0.0
Other changes		—			1.9
Change in valuation allowance		10.2			24.4	%
Total		0.0	%		0.0	%

15 Mar 24

4:09pm

S-1/A

FBLG FibroBiologics, Inc. Common Stock

IPO registration (amended)


(in thousands of dollars)	December 31, 2023		December 31, 2022
Deferred tax assets:
Net operating loss carryforwards	$	2,005	$	896
Capitalized research and development		675		299
Lease liability		367		435
Accrued liabilities		156		81
Stock compensation		123		17
Derivative liability		—		31
Deferred tax assets		3,326		1,759
Deferred tax liabilities:
Lease right-of-use asset		(380)		(462)
Fixed assets		(11)		—
Unamortized debt discount		—		(31)
Deferred tax liabilities		(391)		(493)
Less: Valuation allowance		(2,935)		(1,266)
Net deferred tax assets	$	—	$	—

15 Mar 24

4:09pm

12 Feb 24

5:18pm

S-1

r00a1oco 3mmy4b

IPO registration

12 Feb 24

5:18pm

S-1

69c8a 8sv

IPO registration

12 Feb 24

5:18pm

S-1

cl6gnqg015uwc

IPO registration

12 Feb 24

5:18pm

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.

Table search / FibroBiologics, Inc. Common Stock / "Tax"

12 results

Top filers

Top filing types

Recent filing years